Association of DNA methyltransferase 3A gene expression and polymorphisms with chronic myeloid leukemia susceptibility in an Iraqi cohort
Amna Mouafak Alneaemy, Abdulameer Nasser Al-Rikabi, Alaa Fadhil AlwanAbstract:
BACKGROUND:
While somatic DNA methyltransferase 3A (DNMT3A) mutations are known to drive hematological malignancies, the role of DNMT3A genetic variants and expression changes in chronic myeloid leukemia (CML) remains poorly understood, particularly in the context of tyrosine kinase inhibitor (TKI) therapy.
OBJECTIVES:
This study aimed to investigate the association of
PATIENTS, MATERIALS, AND METHODS:
In this cross-sectional study, 40 CML patients (20 responsive and 20 nonresponsive to bosutinib) and 20 healthy controls were enrolled. DNMT3A mRNA expression was quantified using quantitative real-time polymerase chain reaction.
RESULTS:
DNMT3A expression was significantly downregulated in CML patients compared to healthy controls (
CONCLUSION:
DNMT3A polymorphisms and reduced DNMT3A expression were significantly associated with CML, suggesting a potential role for this epigenetic regulator in disease biology. While these variants may serve as biomarkers for CML susceptibility, the observed downregulation could represent a pharmacodynamic effect of TKI treatment. These findings warrant further investigation into their functional roles and clinical utility.